Compare Crispr Therapeutics AG (CRSP) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Zoom Video Communications, Inc. — how do they compare? Crispr Therapeutics AG trades at $54 (market cap $5.23B), while Zoom Video Communications, Inc. trades at $105.31 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is far larger — about 5.9× Crispr Therapeutics AG's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ZM | |
|---|---|---|
Market Cap | $5.23B | $31.10B |
Sector | Health | Technology |
52-Week High | $76.78 | $111.88 |
52-Week Low | $44.34 | $69.96 |
Enterprise Value | $3.65B | $23.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Zoom Communications (ZM) trades at $104.70, down 2.33% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.4% gross margins and 42% net income margin, though recent earnings show volatility with one miss in the last four quarters. Recent news highlights CEO and director stock sales totaling over $7 million in July-August 2026, while the company continues AI product development and APAC expansion.
Outlook remains cautiously optimistic with a $118.79 consensus price target representing 13% upside potential. Key opportunities include sustained profitability and AI-driven growth initiatives, while risks center on insider selling pressure and competitive threats in the video communications space. The stock faces near-term technical resistance at $107-$109 levels with support at $103-$105.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
